Press Releases and Events
PRESS RELEASES
Press Release | June 30, 2025
Press Release | June 10, 2025
Crinetics Pharmaceuticals Announces June 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
READ MORE
Press Release | May 23, 2025
Crinetics Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2025
READ MORE
Press Release | May 15, 2025
Crinetics to Present New Research on Paltusotine, Atumelnant and Unmet Needs in Acromegaly Treatment at the American Association of Clinical Endocrinology Annual Meeting 2025
READ MORE
Press Release | May 12, 2025
Crinetics Pharmaceuticals Announces May 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
READ MORE
Press Release | May 8, 2025
Crinetics Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
READ MORE
Press Release | April 10, 2025
Crinetics Pharmaceuticals Announces April 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
READ MORE
Press Release | March 27, 2025
Crinetics Pharmaceuticals Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) and Orphan Drug Designation (ODD) for Paltusotine in Acromegaly
READ MORE
Press Release | March 10, 2025
Crinetics Pharmaceuticals Announces March 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
READ MORETransforming Endocrine Disease Treatment
Be the first to know about the advances we're making in endocrine-rooted care.
